ISRCTN17242711已完成未知
INdian COntrolled trial of RITuximab vs Modified Ponticelli regimen for treatment of primary membranous nephropathy
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients older than 18 years who provide written informed consent.
- •2. Biopsy-proven primary MN within 2 years of enrolment with nephrotic range proteinuria denoted by 24-hour urine protein =3.5 g or UPCR (urine protein:creatinine ratio) =3500 mg/g as well as the following:
- •2.1. Serology or biopsy positive for AntiPLA2R
- •2.2. Serology or biopsy negative for AntiPLA2R and secondary causes ruled out
- •2.3. Evaluation for secondary causes was done in all patients, even in patients who were positive for Anti-PLA2R antibodies on serology or PLA2R antigen on biopsy because these have also been found in some cases of secondary MN
- •3. Estimated GFR =30 ml/min/1.73m². The CKD-EPI creatinine equation was used for the calculation of the eGFR
- •4. Treatment with an ACEI or ARB for at least 3 months before enrolment
排除标准
- •1. Secondary MN
- •2. Active serious infections
- •3. Pregnant women
- •4. Suspected or known hypersensitivity to either interventional drug
- •5. Patients with persistently low estimated GFR <30 ml/min/1.73m² in the absence of acute causes such as acute tubular injury, renal vein thrombosis and others
研究者
相似试验
尚未招募
不适用
Comparison between single dose and multiple dose Rituximab in idiopathic membranous nephropathyCTRI/2020/11/029094RS Medical College and Hospital
进行中（未招募）
不适用
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hypMedDRA version: 14.1Level: PTClassification code 10018372Term: Glomerulonephritis membranousSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-006115-59-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
进行中（未招募）
1 期
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVASEUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108
已完成
2 期
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
已完成
2 期
RECIPE TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-jRCT2041180037Iijima Masahiro25